Alliance Pharma PLC has announced a delay in the publication of its preliminary results for the year ended 31 December 2023. The results, initially expected on 23 April 2024, are now anticipated to be released in early May. The Group's auditor, Deloitte LLP, has requested additional time to finalize its work, despite the audit being at an advanced stage. The company plans to provide an update on the new publication date on 26 April 2024. Alliance reaffirms the accuracy of the details provided in the full-year trading update on 29 January 2024.

Alliance Pharma PLC (AIM: APH) is a growing consumer healthcare company with a focus on empowering people to make a positive difference to their health and wellbeing by making trusted and proven brands available worldwide. The company aims for organic growth through investing in priority brands and channels, related innovation, and selective geographic expansion. Additionally, it may consider selective, complementary acquisitions to enhance organic growth. The Group, headquartered in the UK, employs around 285 people across Europe, North America, and the Asia Pacific region. By outsourcing manufacturing and logistics, Alliance Pharma remains asset-light and focused on maximizing the value it brings to stakeholders and brands.

For further information, investors can contact Alliance Pharma directly or through their appointed advisors. Alliance Pharma's purpose is to empower people to make a positive difference to their health and wellbeing by making trusted and proven brands available around the world. The company delivers organic growth through investing in priority brands and channels, related innovation, and selective geographic expansion to increase the reach of its brands. Periodically, it may look to enhance organic growth through selective, complementary acquisitions. Alliance Pharma remains asset-light and focused on maximizing the value it can bring to stakeholders and brands by outsourcing manufacturing and logistics.

This update provides insight into Alliance Pharma's commitment to transparency and accuracy in financial reporting, as well as its strategic focus on empowering individuals to improve their health and wellbeing through the availability of trusted healthcare brands globally.